124 related articles for article (PubMed ID: 9256953)
1. No therapeutic advantage from didanosine (ddI) and hydroxyurea versus ddI alone in patients with HIV infection.
Simonelli C; Comar M; Zanussi S; De Paoli P; Tirelli U; Giacca M
AIDS; 1997 Aug; 11(10):1299-300. PubMed ID: 9256953
[No Abstract] [Full Text] [Related]
2. Interleukin-2 in combination with zidovudine and didanosine is able to maintain high levels of CD4 cells and undetectable HIV viraemia.
Simonelli C; Zanussi S; Comar M; Vaccher E; Giacca M; De Paoli P; Tirelli U
AIDS; 1998 Jan; 12(1):112-3. PubMed ID: 9456263
[No Abstract] [Full Text] [Related]
3. Lowering the dose of hydroxyurea minimizes toxicity and maximizes anti-HIV potency.
Lori F; Pollard RB; Whitman L; Bakare N; Blick G; Shalit P; Foli A; Peterson D; Tennenberg A; Schrader S; Rashbaum B; Farthing C; Herman D; Norris D; Greiger P; Frank I; Groff A; Lova L; Asmuth D; Lisziewicz J
AIDS Res Hum Retroviruses; 2005 Apr; 21(4):263-72. PubMed ID: 15943568
[TBL] [Abstract][Full Text] [Related]
4. More information on hydroxyurea.
Santiago LG
GMHC Treat Issues; 1996 Aug; 10(8):10. PubMed ID: 11363717
[TBL] [Abstract][Full Text] [Related]
5. Systematic review of combination antiretroviral therapy with didanosine plus hydroxyurea: a partial solution to Africa's HIV/AIDS problem?
Sanne I; Smego RA; Mendelow BV
Int J Infect Dis; 2001; 5(1):43-8. PubMed ID: 11285159
[TBL] [Abstract][Full Text] [Related]
6. A placebo-controlled trial of didanosine plus stavudine, with and without hydroxyurea, for HIV infection. The Swiss HIV Cohort Study.
Rutschmann OT; Opravil M; Iten A; Malinverni R; Vernazza PL; Bucher HC; Bernasconi E; Sudre P; Leduc D; Yerly S; Perrin LH; Hirschel B
AIDS; 1998 May; 12(8):F71-7. PubMed ID: 9631134
[TBL] [Abstract][Full Text] [Related]
7. Randomized study of didanosine monotherapy and combination therapy with zidovudine in hemophilic and nonhemophilic subjects with asymptomatic human immunodeficiency virus-1 infection. AIDS Clinical Trial Groups.
Ragni MV; Amato DA; LoFaro ML; DeGruttola V; Van Der Horst C; Eyster ME; Kessler CM; Gjerset GF; Ho M; Parenti DM
Blood; 1995 May; 85(9):2337-46. PubMed ID: 7727768
[TBL] [Abstract][Full Text] [Related]
8. Didanosine, lamivudine, and efavirenz versus zidovudine, lamivudine, and efavirenz for the initial treatment of HIV type 1 infection: final analysis (48 weeks) of a prospective, randomized, noninferiority clinical trial, GESIDA 3903.
Berenguer J; González J; Ribera E; Domingo P; Santos J; Miralles P; Angels Ribas M; Asensi V; Gimeno JL; Pérez-Molina JA; Terrón JA; Santamaría JM; Pedrol E;
Clin Infect Dis; 2008 Oct; 47(8):1083-92. PubMed ID: 18781872
[TBL] [Abstract][Full Text] [Related]
9. Pilot clinical trial of the combination of hydroxyurea and didanosine in HIV-1 infected individuals.
Biron F; Lucht F; Peyramond D; Fresard A; Vallet T; Nugier F; Grange J; Malley S; Hamedi-Sangsari F; Vila J
Antiviral Res; 1996 Jan; 29(1):111-3. PubMed ID: 8721560
[No Abstract] [Full Text] [Related]
10. Activity, safety, and immunological effects of hydroxyurea added to didanosine in antiretroviral-naive and experienced HIV type 1-infected subjects: a randomized, placebo-controlled trial, ACTG 307.
Frank I; Bosch RJ; Fiscus S; Valentine F; Flexner C; Segal Y; Ruan P; Gulick R; Wood K; Estep S; Fox L; Nevin T; Stevens M; Eron JJ;
AIDS Res Hum Retroviruses; 2004 Sep; 20(9):916-26. PubMed ID: 15597521
[TBL] [Abstract][Full Text] [Related]
11. Effect of antiretroviral combination therapy (zidovudine/didanosine or zidovudine/lamivudine) on quantitative plasma human immunodeficiency virus-ribonucleic acid in children and adolescents infected with human immunodeficiency virus.
Sölder B; Wintergerst U; Notheis G; Eberle J; Gürtler L; Belohradsky BH
J Pediatr; 1997 Feb; 130(2):293-9. PubMed ID: 9042135
[TBL] [Abstract][Full Text] [Related]
12. Hydroxyurea and didanosine is a more potent combination than hydroxyurea and zidovudine.
Foli A; Lori F; Maserati R; Tinelli C; Minoli L; Lisziewicz J
Antivir Ther; 1997 Jan; 2(1):31-8. PubMed ID: 11322264
[TBL] [Abstract][Full Text] [Related]
13. Hydroxyurea for HIV infection.
Zachary KC; Davis B
AIDS Clin Care; 1998 Apr; 10(4):25-6, 32. PubMed ID: 11365149
[TBL] [Abstract][Full Text] [Related]
14. Human immunodeficiency virus type 1 (HIV-1) viremia changes and development of drug-related mutations in patients with symptomatic HIV-1 infection receiving alternating or simultaneous zidovudine and didanosine therapy.
Kojima E; Shirasaka T; Anderson BD; Chokekijchai S; Steinberg SM; Broder S; Yarchoan R; Mitsuya H
J Infect Dis; 1995 May; 171(5):1152-8. PubMed ID: 7751690
[TBL] [Abstract][Full Text] [Related]
15. Didanosine plus stavudine with or without hydroxyurea in HIV-1-infected patients: 1 year follow-up. Swiss HIV Cohort Study.
Rutschmann OT; Opravil M; Iten A; Malinverni R; Vernazza PL; Bucher H; Bernasconi E; Perrin LH; Yerly S; Hirschel B
Antivir Ther; 1998; 3 Suppl 4():65-7. PubMed ID: 10723515
[TBL] [Abstract][Full Text] [Related]
16. Enhanced HIV-specific immune responses in chronically HIV-infected patients receiving didanosine plus hydroxyurea.
López M; Benito JM; Lozano S; Barreiro P; Martínez P; González-Lahoz J; Soriano V
AIDS; 2004 Jun; 18(9):1251-61. PubMed ID: 15362657
[TBL] [Abstract][Full Text] [Related]
17. Hydroxyurea plus didanosine as maintenance therapy for HIV-infected patients on long-term successful highly active antiretroviral therapy.
Barreiro P; de Mendoza C; Camino N; García-Benayas T; Blanco F; Núñez M; González-Lahoz J; Soriano V
HIV Clin Trials; 2003; 4(6):361-71. PubMed ID: 14628279
[TBL] [Abstract][Full Text] [Related]
18. A randomized, dose-finding study with didanosine plus stavudine versus didanosine alone in antiviral-naive, HIV-infected Thai patients.
Ruxrungtham K; Kroon ED; Ungsedhapand C; Teeratakulpisarn S; Ubolyam S; Buranapraditkun S; van Leeuwen R; Weverling GJ; Kunanusont C; Lange JM; Cooper DA; Phanuphak P
AIDS; 2000 Jul; 14(10):1375-82. PubMed ID: 10930152
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic advantage of hydroxyurea and didanosine combination therapy in patients previously treated with zidovudine.
Foli A; Maserati R; Minoli L; Wainberg MA; Gallo RC; Lisziewicz J; Lori F
AIDS; 1998 Jun; 12(9):1113-4. PubMed ID: 9662215
[No Abstract] [Full Text] [Related]
20. Dethroning AZT.
Gilden D; Falkenberg J; Torres G
GMHC Treat Issues; 1997 Feb; 11(2):10-3. PubMed ID: 11364106
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
